Simlukafusp alfa

DB16092InvestigationalProtein Based Therapies

RO6874281 is under investigation in clinical trial NCT03193190 (A Study of Multiple Immunotherapy-based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-pancreatic Cancer)).

Mechanism: Pharmacologically active on Prolyl endopeptidase FAP
Curator reviewed
Also known as: Anti-fap/interleukin-2 fusion protein ro6874281
Code names: FAP-IL2V FP RO6874281 · RG-7461 · RO-6874281

Resolves to

Compound

UNIIFL08SGO9XACAS1776942-10-9

Targets

Q12884FAP

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Simlukafusp alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account